SPOTLIGHT: Fledgling biotech hunts for cash


The backers of a fledgling northern Virginia biotech named Cary Pharmaceuticals has been out beating the bushes for $14 million in new investment funds to carry the company into the clinic. So far, about $2.6 million has been raised from family, friends, a federal grant and a manufacturing partner. Report

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.